HOME >> MEDICINE >> NEWS
OneWorld Health licenses compounds from Yale, U of Washington to treat major parasitic diseases

San Francisco, Calif. July 8, 2003 -- The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, announced today it has licensed a novel class of high-potency compounds from Yale University and the University of Washington that could result in medicines for the developing and developed worlds.

The agreement gives OneWorld Health the exclusive license to develop the azole compounds to treat parasitic diseases in the developing world. OneWorld Health will initially focus on the use of the azoles in Chagas disease, the leading cause of heart failure in Latin America, where 16 to 18 million people are infected and another 100 million are at risk. The disease is most often transmitted by an insect known as the "kissing bug," but may also be transmitted by blood transfusion. At least 50,000 to 100,000 people in the U.S. are infected as well.

The licensing agreement also creates a dual market opportunity in which the universities could seek a pharmaceutical partner to develop the same compounds for fungal infections in industrialized countries.

OneWorld Health will conduct appropriate pre-clinical tests after selecting a lead candidate among the compounds, which represent the first new potential drugs to treat Chagas disease in decades. The compounds were developed by teams led by Andrew Hamilton, deputy provost for science and technology at Yale and professor of chemistry, in collaboration with Frederick Buckner, Michael Gelb, Wesley Van Voorhis, and Kohei Yokoyama, all professors at the University of Washington in Seattle.

"We are delighted that these potent anti-Chagas agents have been licensed to an organization that is committed to their development for treatment of this terrible parasitic disease," said Hamilton, of Yale. "We look forward to working with OneWorld Health to produce drug leads that will push these compounds into pre-clinical development and beyond."

"There is more optim
'"/>

Contact: Sedef Onder
sonder@thehaloproject.com
917-570-8934
Institute for OneWorld Health
8-Jul-2003


Page: 1 2 3

Related medicine news :

1. OneWorld Health begins final testing of drug to cure deadly kala azar in India
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Liverpool to lead 20M Department of Health initiative to develop medicines for children
4. Health care report cards may increase racial/ethnic disparities in bypass operations
5. 2005 Behavioral Sciences & Health Services Research Award
6. Statement on the findings of the Womens Health Study
7. Bone density returns when teens stop using Depo Provera, Group Health study finds
8. Mailman School of Public Health researchers develop infectious disease diagnostic tool
9. Health initiatives can help peace building in the Middle East
10. Study naming hospitals in top 5% for clinical quality released by HealthGrades
11. RelayHealth selected by Columbia University to link doctors and patients online

Post Your Comments:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... for Women’s Cancer announce today that Dr. Beth ... of the Claudia Cohen Research Foundation Prize for Outstanding ... the Society of Gynecologic Oncology 46th Annual Meeting on ... of the Cedars-Sinai Women’s Cancer Program at the Samuel ...
(Date:3/29/2015)... 29, 2015 Youth Villages will participate ... Oregon to assess the feasibility of implementing a Pay ... behavioral problems and their families. , Third Sector Capital ... that will be provided technical assistance throughout 2015 toward ... six other national awardees chosen by Third Sector. The ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural body ... new natural sunscreen. They are offering the sunscreen in ... come with a bonus lip balm sunscreen. , The new ... Click to see the natural sunscreen on Amazon . ... made with non-nano zinc oxide and provides broad-based protection against ...
(Date:3/28/2015)... Take a bite of warm, gooey ... Acids tumble into the stomach, ready to break down ... lets these acids run amok, triggering a burning sensation ... More than 60 million Americans have heartburn at least ... starts, and how it can be stopped. , Heartburn ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
(Date:3/29/2015)...  Three-month paliperidone palmitate, an investigational atypical antipsychotic, ... in patients with schizophrenia, according to a new ... the Journal of the American Medical ... of the study served as the basis for ... three-month paliperidone palmitate injection to treat schizophrenia in ...
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... , March 27, 2015 Across the ... to meeting challenges in clinical development, market education, and ... regulations, the Medical Affairs function is expected to increase ... markets. According to research by benchmarking ... have a group dedicated to Medical Affairs. Among companies ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
Cached News: